Interferon-β 1a inhibits SARS-CoV-2 in vitro when administered after virus infection
| Autor: | Clementi N., Ferrarese R., Criscuolo E., Diotti R. A., Castelli M., Scagnolari C., Burioni R., Antonelli G., Clementi M., Mancini N., CRISCUOLO , ELENA |
|---|---|
| Přispěvatelé: | Clementi, N., Ferrarese, R., Criscuolo, E., Diotti, R. A., Castelli, M., Scagnolari, C., Burioni, R., Antonelli, G., Clementi, M., Mancini, N., Criscuolo, Elena |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Popis: | The ongoing COVID-19 pandemic has forced the clinical and scientific community to try drug repurposing of existing antiviral agents as a quick option against SARS-CoV-2. Under this scenario, the interferon-β 1a (IFN-β 1a) whose antiviral potential is already known, and is a drug currently used in the clinical management of multiple sclerosis, may represent as a potential candidate. In this report, we demonstrate that IFN-β 1a was highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically achievable concentration when administered after virus infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|